{"id":70353,"date":"2026-07-21T19:14:51","date_gmt":"2026-07-21T11:14:51","guid":{"rendered":"https:\/\/flcube.com\/?p=70353"},"modified":"2026-07-21T19:14:52","modified_gmt":"2026-07-21T11:14:52","slug":"insilico-medicine-forms-quantum-ai-alliance-with-byterna-and-duneq-to-accelerate-next-generation-rna-and-peptide-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70353","title":{"rendered":"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>) has signed a <strong>tripartite strategic cooperation agreement<\/strong> with <strong>Byterna Therapeutics<\/strong>, a biopharmaceutical company specializing in next-generation intelligent R&amp;D of <strong>in vivo RNA therapies<\/strong> including <strong>in vivo CAR-T<\/strong>, and <strong>DuneQ<\/strong>, a frontier technology enterprise developing the <strong>next-generation peptide drug design platform (HQL)<\/strong> that integrates <strong>quantum computing and AI<\/strong>. The collaboration aims to leverage <strong>quantum computing advantages<\/strong> to enhance generative AI capabilities and accelerate the development of novel therapeutic modalities across RNA, peptide, and cell therapy platforms.<\/p>\n\n\n\n<h2 id=\"h-partnership-structure-amp-strategic-investments\" class=\"wp-block-heading\">Partnership Structure &amp; Strategic Investments<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Lead Partner<\/strong><\/td><td>Insilico Medicine (HKG: 3696)<\/td><\/tr><tr><td><strong>Biotech Partner<\/strong><\/td><td>Byterna Therapeutics (in vivo RNA therapies, in vivo CAR-T)<\/td><\/tr><tr><td><strong>Technology Partner<\/strong><\/td><td>DuneQ (quantum computing + AI peptide platform)<\/td><\/tr><tr><td><strong>Investment Component<\/strong><\/td><td>Insilico participated as strategic investor in Byterna&#8217;s Pre-A round (tens of millions RMB)<\/td><\/tr><tr><td><strong>Funding Purpose<\/strong><\/td><td>Clinical advancement of in vivo CAR-T and cancer vaccine pipelines; joint AI-native mRNA R&amp;D engine<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>July 21, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-integration-framework\" class=\"wp-block-heading\">Technology Integration Framework<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Insilico Medicine Contribution:<\/strong> Full deployment of proprietary <strong>end-to-end generative AI platform, Pharma.AI<\/strong><\/li>\n\n\n\n<li><strong>DuneQ Contribution:<\/strong> Computational power support and <strong>high-precision synthetic data<\/strong> from <strong>Heterogeneous Quantum Physics Engine (HQL)<\/strong><\/li>\n\n\n\n<li><strong>Byterna Contribution:<\/strong> Innovative application scenarios including:<\/li>\n\n\n\n<li>Circular mRNA sequence design<\/li>\n\n\n\n<li>In vivo lipid nanoparticle delivery systems (tLNP)<\/li>\n\n\n\n<li>Personalized cancer vaccine design<\/li>\n\n\n\n<li><strong>Validation Objective:<\/strong> Demonstrate feasibility and performance advantages of <strong>&#8220;Quantum + AI&#8221; closed-loop system<\/strong> in real-world drug discovery applications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-innovation-pipeline\" class=\"wp-block-heading\">Strategic Rationale &amp; Innovation Pipeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Modality Focus:<\/strong> Addresses emerging therapeutic categories including in vivo CAR-T, mRNA vaccines, and quantum-designed peptides<\/li>\n\n\n\n<li><strong>Technology Synergy:<\/strong> Combines generative AI&#8217;s pattern recognition with quantum computing&#8217;s computational precision for complex biological problems<\/li>\n\n\n\n<li><strong>Platform Scalability:<\/strong> Creates reusable infrastructure for multiple therapeutic modalities beyond initial focus areas<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> First-of-its-kind integration of quantum computing specifically optimized for biopharmaceutical R&amp;D<\/li>\n\n\n\n<li><strong>Speed-to-Clinic:<\/strong> Aims to compress traditional drug discovery timelines through enhanced computational prediction accuracy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-industry-implications\" class=\"wp-block-heading\">Market Context &amp; Industry Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Drug Discovery Evolution:<\/strong> Represents next-generation convergence of multiple advanced technologies beyond standard machine learning<\/li>\n\n\n\n<li><strong>Quantum Computing Applications:<\/strong> Demonstrates practical near-term applications of quantum computing in life sciences<\/li>\n\n\n\n<li><strong>In Vivo Cell Therapy:<\/strong> Addresses technical challenges in delivering cell therapies without ex vivo manufacturing complexity<\/li>\n\n\n\n<li><strong>Personalized Medicine:<\/strong> Enables rapid design and optimization of patient-specific therapeutic candidates<\/li>\n\n\n\n<li><strong>Investment Validation:<\/strong> Strategic investment by Insilico signals confidence in Byterna&#8217;s technology platform and clinical potential<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The tripartite alliance positions the partners at the forefront of computational drug discovery, creating a unique ecosystem that combines cutting-edge AI, quantum computing, and innovative therapeutic modalities to address previously intractable drug development challenges.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding technology integration, partnership outcomes, and development timelines. Actual results may differ due to technical feasibility, regulatory requirements, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70354,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,93],"tags":[99,4457,4514,164],"class_list":["post-70353","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-digital","tag-ai","tag-byterna-therapeutics","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a biopharmaceutical company specializing in next-generation intelligent R&amp;D of in vivo RNA therapies including in vivo CAR-T, and DuneQ, a frontier technology enterprise developing the next-generation peptide drug design platform (HQL) that integrates quantum computing and AI. The collaboration aims to leverage quantum computing advantages to enhance generative AI capabilities and accelerate the development of novel therapeutic modalities across RNA, peptide, and cell therapy platforms.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70353\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a biopharmaceutical company specializing in next-generation intelligent R&amp;D of in vivo RNA therapies including in vivo CAR-T, and DuneQ, a frontier technology enterprise developing the next-generation peptide drug design platform (HQL) that integrates quantum computing and AI. The collaboration aims to leverage quantum computing advantages to enhance generative AI capabilities and accelerate the development of novel therapeutic modalities across RNA, peptide, and cell therapy platforms.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70353\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-21T11:14:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-21T11:14:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics\",\"datePublished\":\"2026-07-21T11:14:51+00:00\",\"dateModified\":\"2026-07-21T11:14:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353\"},\"wordCount\":455,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2104.webp\",\"keywords\":[\"AI\",\"Byterna Therapeutics\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Deals\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70353#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70353\",\"name\":\"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2104.webp\",\"datePublished\":\"2026-07-21T11:14:51+00:00\",\"dateModified\":\"2026-07-21T11:14:52+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a biopharmaceutical company specializing in next-generation intelligent R&D of in vivo RNA therapies including in vivo CAR-T, and DuneQ, a frontier technology enterprise developing the next-generation peptide drug design platform (HQL) that integrates quantum computing and AI. The collaboration aims to leverage quantum computing advantages to enhance generative AI capabilities and accelerate the development of novel therapeutic modalities across RNA, peptide, and cell therapy platforms.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70353\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2104.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70353#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a biopharmaceutical company specializing in next-generation intelligent R&D of in vivo RNA therapies including in vivo CAR-T, and DuneQ, a frontier technology enterprise developing the next-generation peptide drug design platform (HQL) that integrates quantum computing and AI. The collaboration aims to leverage quantum computing advantages to enhance generative AI capabilities and accelerate the development of novel therapeutic modalities across RNA, peptide, and cell therapy platforms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70353","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics","og_description":"Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a biopharmaceutical company specializing in next-generation intelligent R&D of in vivo RNA therapies including in vivo CAR-T, and DuneQ, a frontier technology enterprise developing the next-generation peptide drug design platform (HQL) that integrates quantum computing and AI. The collaboration aims to leverage quantum computing advantages to enhance generative AI capabilities and accelerate the development of novel therapeutic modalities across RNA, peptide, and cell therapy platforms.","og_url":"https:\/\/flcube.com\/?p=70353","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-21T11:14:51+00:00","article_modified_time":"2026-07-21T11:14:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70353#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70353"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics","datePublished":"2026-07-21T11:14:51+00:00","dateModified":"2026-07-21T11:14:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70353"},"wordCount":455,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70353#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2104.webp","keywords":["AI","Byterna Therapeutics","HKG: 3696","Insilico Medicine"],"articleSection":["Company","Deals","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70353#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70353","url":"https:\/\/flcube.com\/?p=70353","name":"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70353#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70353#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2104.webp","datePublished":"2026-07-21T11:14:51+00:00","dateModified":"2026-07-21T11:14:52+00:00","description":"Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a biopharmaceutical company specializing in next-generation intelligent R&D of in vivo RNA therapies including in vivo CAR-T, and DuneQ, a frontier technology enterprise developing the next-generation peptide drug design platform (HQL) that integrates quantum computing and AI. The collaboration aims to leverage quantum computing advantages to enhance generative AI capabilities and accelerate the development of novel therapeutic modalities across RNA, peptide, and cell therapy platforms.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70353#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70353"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70353#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2104.webp","width":1080,"height":608,"caption":"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70353#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70353"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70353\/revisions"}],"predecessor-version":[{"id":70355,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70353\/revisions\/70355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70354"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}